juin 24, 2020

Academia developing medicines for rare diseases to receive free EMA scientific advice

The EMA has decided to waive all fees for scientific advice for academic researchers developing orphan medicines, to further encourage the development of treatments for rare diseases. The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with…

FDA new grant funding opportunity

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2021 – FY 2022 to support innovative and efficient clinical trials for rare diseases and conditions. These studies are intended to provide acceptable data to the FDA that will substantially contribute to…